MEDILINK THERAPEUTICS
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.
MEDILINK THERAPEUTICS
Industry:
Biotechnology Genetics Therapeutics
Founded:
2020-01-01
Address:
Suzhou, Jiangsu, China
Country:
China
Status:
Active
Total Funding:
120 M USD
Similar Organizations
Laekna Therapeutics
Laekna Therapeutics is a biotech company focusing on drug discovery and development.
Current Employees Featured
Founder
Investors List
Loyal Valley Capital
Loyal Valley Capital investment in Series B - Medilink Therapeutics
Legend Capital
Legend Capital investment in Series B - Medilink Therapeutics
Qiming Venture Partners
Qiming Venture Partners investment in Series B - Medilink Therapeutics
LYFE Capital
LYFE Capital investment in Series B - Medilink Therapeutics
Highlight Capital
Highlight Capital investment in Series B - Medilink Therapeutics
Loyal Valley Capital
Loyal Valley Capital investment in Series A - Medilink Therapeutics
Apricot Capital
Apricot Capital investment in Series A - Medilink Therapeutics
Qiming Venture Partners
Qiming Venture Partners investment in Series A - Medilink Therapeutics
More informations about "Medilink Therapeutics"
Medilink Therapeutics
Medilink Therapeutics focuses on developing internationally competitive drug conjugates, as well as the latest generation of technologies and products with independent intellectual property …See details»
Medilink Therapeutics - Crunchbase Company Profile …
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through …See details»
Medilink Therapeutics
Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. ADC drugs have both the powerful killing effects of the small …See details»
MediLink Therapeutics Company Profile 2024: Valuation, Funding ...
Developer of antibody-drug conjugates (ADC) based in China. The company focuses on providing patients with ADC therapeutics that combat cancer while sparing healthy cells, keeping …See details»
Medilink Therapeutics
Dr. Xue has more than 10 years of experience in the R&D, production, and domestic & international cooperation of biotechnology drugs, innovative small molecule drugs, and ADC drugs.See details»
MediLink Therapeutics - LinkedIn
MediLink Therapeutics strives to upgrade technologies, establish diverse technology platforms for drug conjugates, and expand into new disease areas to serve global patients continuously....See details»
MediLink Therapeutics Announces Strategic …
Oct 12, 2023 · MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a differentiated proprietary Tumor...See details»
MediLink Therapeutics Announces Strategic Collaboration and
Oct 12, 2023 · MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a …See details»
MediLink Therapeutics Announces Worldwide …
Jan 2, 2024 · MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a differentiated proprietary Tumor...See details»
MediLink Therapeutics Announces Strategic …
SUZHOU, China, Oct. 12, 2023 /PRNewswire/ — MediLink Therapeutics (“MediLink”), announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE (Nasdaq: …See details»
Medilink Therapeutics
Oct 8, 2024 · MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing conjugated drugs with global competitiveness. MediLink has …See details»
MediLink Therapeutics Announces Strategic Collaboration ... - Cooley
Palo Alto – October 12, 2023 – Cooley advised MediLink Therapeutics, a clinical-stage biotech company focused on developing globally competitive conjugated drugs, on its strategic …See details»
MediLink Therapeutics announces a multi-target TMALIN® ADC …
May 27, 2024 · MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nasdaq: BNTX, …See details»
BioNTech Nets MediLink ADC in Potential $1B Cancer Deal
Oct 12, 2023 · MediLink Therapeutics has a deal with BioNTech for development of a next-generation antibody-drug conjugate candidate (ADC) against Human Epidermal Growth Factor …See details»
Medilink Therapeutics Raises $50 Million in Series A Financing
Mar 1, 2021 · Founded in 2020, MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to …See details»
FDA allows BioNTech-MediLink ADC trial to resume at lower doses
Aug 19, 2024 · The FDA has allowed MediLink Therapeutics to restart a phase 1 trial of its BioNTech-partnered antibody-drug conjugate (ADC) that saw three fatalities after the …See details»
MediLink Announces Global Clinical Trial Collaboration and Supply ...
Oct 8, 2024 · MediLink has announced the data of a Phase I/II clinical trial of YL201 in patients with advanced solid tumors including SCLC as a selected oral presentation at the ESMO …See details»
MediLink and BioNTech Sign $1.8 Billion ADC Deal to Expand …
On May 26, 2024, MediLink Therapeutics announced the new partnership with BioNTech, which builds upon their initial collaboration from October 2023. Under this new agreement, BioNTech …See details»
MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6 …
Sep 13, 2024 · MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing conjugated drugs with global competitiveness.See details»